No Data
No Data
Medicenna Reports First "Complete Responder" With MDNA11 Monotherapy, Q1 Results
Medicenna Brief: Increased Cash Balance to US$37 Million Following a $20 Million Investment by RA Capital Extending Runway Into Mid-2026
Medicenna Brief: Net Loss for the Year Ended March 31, 2024, Was US$25.5 Million or $0.37 per Share
Medicenna Secures European Approval for Phase 1/2 ABILITY-1 Study to Europe
Medicenna Brief: Reporting "Significant" Survival Benefit in Patients With Recurrent Glioblastoma Following Treatment With Bizaxofusp When Compared to a "Matched External Control Arm"
Medicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response With MDNA11 in the Dose Escalation Portion of Phase 1/2 ABILITY-1 Study at the 10th Annual Oncology Innovation Forum